Biotech Holdings Announces Effective Induction of "Reverse Abscopal Effect" in Rheumatoid Arthritis Using Procell Activated Stem Cells

SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Biotech Holdings announced today filing of a patent application entitled "Reverse Abscopal Effect for Treatment of Autoimmunity."  The patent covers recent data showing that injection of ProCell stem cells in one joint of animals suffering from rheumatoid arthritis leads to remission of the disease in all the joints.

The term "abscopal effect" is derived from the area of oncology, in which localized irradiation of cancers in one part of the body, results in tumors regressing at anatomically distant locations, likely as a result of immune system activation.

Scientific collaborators of Biotech Holdings found that administration of Procell leads to generation of T regulatory cells, which enter circulation and suppress autoimmune attack on the other joints.

"In autoimmune diseases, conditions where the body's immune system attacks healthy cells of the body, the T regulatory cell plays a fundamental role in specifically stopping the ongoing pathological immune response," said Thomas Ichim, Ph.D, President and CEO of Biotech Holdings. "Unfortunately, the specific molecules of the body that the immune system is attacking in autoimmunity are different from patient to patient and are not fully known.  Accordingly, the finding that Procell can cause remission of autoimmunity, without the need to know patient-specific molecules, places this approach in an ideal position."

According to the NIH, 50 million of Americans suffer from autoimmune diseases, which are one of the top 10 cause of death in women under the age 65. It is estimated that 75% of autoimmune patients are female.

About Biotech Holdings

Biotech Holdings was founded on technologies and patents developed by Dr. Amit Patel and Dr. Thomas Ichim focused on identifying interactions between gut bacteria (microbiome) and stem cells.  The Company has identified several bacterially derived compounds that enhance stem cell activity and is applying these to chronic diseases associated with circulation deficiencies.  Initial therapeutic indications the company is targeting are: Critical Limb Ischemia and Ischemic Heart Failure.  The Company has 10 patent applications filed covering stem cell modulation, augmentation, and differentiation by bacterial compounds.

Contacts

Thomas E Ichim, Ph.D
President and Chief Executive Officer
BioTech Holdings
9255 Towne Centre Drive, #450
San Diego, CA 92121
[email protected] 
858 353 4303
Twitter: @biotechholdings

SOURCE BioTech Holdings